K. Merk

610 total citations
14 papers, 407 citations indexed

About

K. Merk is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, K. Merk has authored 14 papers receiving a total of 407 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pathology and Forensic Medicine, 6 papers in Oncology and 4 papers in Genetics. Recurrent topics in K. Merk's work include Lymphoma Diagnosis and Treatment (7 papers), Viral-associated cancers and disorders (4 papers) and Chronic Lymphocytic Leukemia Research (4 papers). K. Merk is often cited by papers focused on Lymphoma Diagnosis and Treatment (7 papers), Viral-associated cancers and disorders (4 papers) and Chronic Lymphocytic Leukemia Research (4 papers). K. Merk collaborates with scholars based in Sweden, Malaysia and Cuba. K. Merk's co-authors include Magnus Björkholm, Göran Holm, B Gullbring, Anders Mattsson, Britta Mattsson, Gunnar Grimfors, Martin Hollmann, Carolin D. Obermaier, Klaus Förstemann and René Böttcher and has published in prestigious journals such as Nucleic Acids Research, Cancer and Annals of Oncology.

In The Last Decade

K. Merk

14 papers receiving 392 citations

Peers

Countries citing papers authored by K. Merk

Since Specialization

Citations

This map shows the geographic impact of K. Merk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K. Merk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K. Merk more than expected).

Fields of papers citing papers by K. Merk

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K. Merk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K. Merk. The network helps show where K. Merk may publish in the future.

Co-authorship network of co-authors of K. Merk

This figure shows the co-authorship network connecting the top 25 collaborators of K. Merk. A scholar is included among the top collaborators of K. Merk based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K. Merk. K. Merk is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work	Indexed citations
1	Efficient chromosomal gene modification with CRISPR/cas9 and PCR-based homologous recombination donors in cultured Drosophila cells 2014 ·Nucleic Acids Research ·René Böttcher, Martin Hollmann, K. Merk, (unknown), Carolin D. Obermaier, Julia Philippou‐Massier, Ilse Wieland, Ulrike Gaul, Klaus Förstemann	91
2	Addition of etoposide to CHOP chemotherapy in untreated patients with high-grade non-Hodgkin’s lymphoma 1998 ·Annals of Oncology ·Fredrik Celsing, Susanne Widell, K. Merk, Per Bernell, Gunnar Grimfors, (unknown), Jan Liliemark, Erik Svedmyr, E. Ösby, Magnus Björkholm	9
3	Fixed versus response-adapted MOPP/ABVD chemotherapy in Hodgkin's disease 1995 ·Annals of Oncology ·Magnus Björkholm, Ulla Axdorph, Gunnar Grimfors, K. Merk, B. Johansson, Ola Landgren, Erik Svedmyr, Håkan Mellstedt, G. Holm	28
4	Disease-related differences in antibody patterns against EBV-encoded nuclear antigens EBNA 1, EBNA 2 and EBNA 6 1993 ·European Journal of Cancer ·Evelyne T. Lennette, Lars Rymo, (unknown), Giuseppe Masucci, K. Merk, László Tı́már, George Klein	54
5	A Combination of Granulocvte Colonv-Stimulating Factor and Erythiopoietin may Synergistically Improve the Anaemia in Patients with Myelodysplastic Syndromes 1993 ·Leukemia & lymphoma ·Eva Hellström-Lindberg, Gunnar Birgegård, Magnus Carlsson, Jan Carneskog, (unknown), Ingunn Dybedal, Gunnar Grimfors, K. Merk, Jon‐Magnus Tangen, Ingemar Winqvist, (unknown)	52
6	Low dose cyclophosphamide, alpha-interferon and continuous infusions of interleukin-2 in advanced renal cell carcinoma 1993 ·Medical Oncology and Tumor Pharmacotherapy ·Jan Wersäll, Giuseppe Masucci, (unknown), Peter Ragnhammar, Jan Fagerberg, Jan‐Erik Frödin, K. Merk, C. Lindemalm, K. Ericson, Bo Kalin, Håkan Mellstedt	12
7	Lymphocyte abnormalities predicting a poor prognosis in Hodgkin's disease. A long-term follow-up 1991 ·Cancer ·(unknown), Gunnar Grimfors, G. Holm, Bo Johansson, Erik Svedmyr, C. Wedelin, Håkan Mellstedt, K. Merk, Magnus Björkholm	27
8	Mitoxantrone, etoposide, cytarabine and prednisone as salvage therapy for refractory non‐Hodgkin lymphoma (NHL) and alternated with CHOP in previously untreated patients with NHL 1991 ·European Journal Of Haematology ·K. Merk, (unknown), Bo Johansson, Eva Kimby, C. Lindemalm, E. Ösby, Magnus Björkholm	8
9	The Incidence of Cancer among Blood Donors 1990 ·International Journal of Epidemiology ·K. Merk, Britta Mattsson, Anders Mattsson, Göran Holm, B Gullbring, Magnus Björkholm	75
10	Increased incidence of Kaposi sarcoma in Sweden before the AIDS epidemic 1990 ·European Journal of Cancer and Clinical Oncology ·Niels Bendsøe, Michael Dictor, Jonas Blomberg, (unknown), K. Merk	15
11	Epidemiological Study of Hodgkin’s Disease in Cuba and Sweden 1990 ·Oncology ·K. Merk, Magnus Björkholm, (unknown), (unknown), G. Holm, (unknown)	13
12	Immune deficiency in family members of patients with Hodgkin's disease 1990 ·Cancer ·K. Merk, Magnus Björkholm, (unknown), Håkan Mellstedt, Göran Holm	10
13	Delayed skin hypersensitivity in man. The effect of repeated tests with low-dose antigen. 1988 ·PubMed ·K. Merk, Magnus Björkholm, G. Holm, H Mellstedt	1
14	Cyclic autoimmune hemolytic anemia as a presenting manifestation of splenic Hodgkin's disease 1982 ·Cancer ·Magnus Björkholm, Göran Holm, K. Merk	12

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact